Comparing the current results to its competitors, Cybin Inc reported Revenue increase in the 4 quarter 2025 by 123.74 % year on year. The sales growth was above Cybin Inc 's competitors' average revenue growth of 120.23 %, achieved in the same quarter.
Cybin Inc 's Comment on Competition and Industry Peers
The Company manages the disclosure of project timing and costs in accordance with pharmaceutical industry practices, releasing this information only alongside financial statements and key milestones. This approach is intended to protect patent and intellectual property rights by avoiding premature disclosure of proprietary data.
Alzamend Neuro Inc is a biopharmaceutical company specializing in the development and commercialization of innovative therapeutics for Alzheimer's disease and other neurological disorders. Their business model revolves around conducting extensive research and clinical trials to develop groundbreaking treatments that address the underlying causes of these debilitating conditions. With a focus on creating value for patients, healthcare providers, and shareholders, they aim to bring effective therapies to market and improve the quality of life for those affected by neurodegenerative diseases.
Atai Life Sciences Nv is a biotech company focused on developing innovative treatments for mental health disorders. They utilize a multi-disciplinary approach that combines scientific research, clinical trials, and partnerships to accelerate the discovery and development of psychedelic medicines. Using a patient-centric approach, Atai aims to address unmet needs in the mental health space and improve the lives of individuals suffering from these conditions.
Biocorrx Inc is a pharmaceutical company that primarily focuses on providing medication-assisted treatment for substance use disorders. Their business model revolves around the development and commercialization of their proprietary naltrexone implant, coupled with a supportive counseling program. By offering an implant that delivers continuous medication over an extended period, Biocorrx aims to enhance treatment efficacy, reduce relapse rates, and provide a comprehensive solution for individuals struggling with addiction.
Clearmind Medicine Inc operates as a healthcare company that provides innovative mental health solutions, leveraging advanced technology and research-backed treatments. Their business model focuses on developing and delivering personalized mental health therapies, utilizing a combination of telehealth services, virtual reality technology, and data-driven treatment plans.
Compass Pathways Plc is a mental healthcare company focused on developing innovative therapies for treatment-resistant depression. They are pioneering the use of psychedelic-assisted therapy to address this significant unmet medical need. With a business model centered around clinical research and drug development, their goal is to bring their therapies to market and improve the lives of patients suffering from depression.
Sources:
Cybin Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Cybin Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
